TIB MOLBIOL, a Roche Diagnostics subsidiary, has launched the CE‑marked LightMix Newborn TREC/SMN1/HBB kit for simultaneous screening of SCD, SMA and SCID on LightCycler systems. The ready‑to‑use assay is aimed at academic and private hospital laboratories as a first‑tier screen to trigger confirmatory testing and early intervention. Early detection enables timely treatments that can prevent severe complications and improve long‑term outcomes.
Roche's TIB MOLBIOL Unveils LightMix Newborn Kit to Screen SCD, SMA and SCID at Birth
The kit is intended for academic and private hospital laboratories to support early detection and prompt medical intervention. Credit: New Africa / Shutterstock.com.
TIB MOLBIOL, a Roche Diagnostics subsidiary, has launched the LightMix Newborn TREC/SMN1/HBB in vitro diagnostic kit to enable rapid, first‑tier screening for three serious newborn conditions in CE‑marked markets.
About the LightMix Newborn Kit
The ready‑to‑use assay runs on LightCycler systems and simultaneously evaluates newborn samples for sickle cell disease (SCD), spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID). It is designed for use by academic and private hospital laboratories as a screening tool to prompt confirmatory diagnostic testing and clinical follow‑up.
Why Early Screening Matters
Detecting these disorders at birth gives clinicians actionable data that can change outcomes. Early identification allows timely interventions that often prevent severe complications and improve long‑term prognosis.
Sickle Cell Disease (SCD)
SCD is caused by a mutation in the hemoglobin subunit beta (HBB) gene that makes red blood cells rigid and prone to premature breakdown. Newborn detection enables preventive care such as prophylactic penicillin, specialised immunisations and early clinical monitoring.
Spinal Muscular Atrophy (SMA)
SMA typically results from homozygous deletions of exon 7 in the survival motor neuron 1 (SMN1) gene and leads to progressive loss of motor neurons and muscle weakness. Identifying SMA at birth allows clinicians to begin targeted therapies immediately, when they are most effective.
Severe Combined Immunodeficiency (SCID)
SCID is characterised by absent or nonfunctional T cells, leaving infants extremely vulnerable to infections. Early screening can enable lifesaving interventions such as hematopoietic stem cell transplantation or enzyme replacement before severe infections occur.
'When a baby is born with a condition such as SMA or SCID, every single day matters,' said Marcus Droege, CEO of TIB MOLBIOL. 'Catching these diseases before symptoms appear can be the difference between a child thriving or facing severe, lifelong disability. By broadening our CE‑compliant newborn screening solutions across Europe, we help laboratories adopt high‑precision workflows that reduce the risk of missed critical diagnoses.'
Company Background And Regulatory Note
Headquartered in Germany, TIB MOLBIOL was founded in 1990 as an oligonucleotide producer and now supplies modular and ready‑to‑use molecular PCR assays for infectious and genetic diseases. The LightMix Newborn kit is available in markets that accept the CE mark. Separately, Roche recently received FDA clearance for the Elecsys pTau217 blood test for Alzheimer’s disease assessment.
Practical Use: The kit is intended as a first‑tier screen to accelerate confirmatory testing and early clinical intervention, not as a definitive diagnostic test on its own.
Help us improve.
